Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-4

Journal of Medicinal Chemistry

Volumn 48, Issue 12, 2005, Pages 4087-4099

  Pettit, George R ^a   Rhodes, Monte R ^a   Herald, Delbert L ^a   Hamel, Ernest ^b   Schmidt, Jean M ^a   Pettit, Robin K ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' [2'' (2'' PYRIDYL)ETHYL]COMBRETASTATIN A4; 3' AMINO 3,4,4',5 TETRAMETHOXY STILBENE; 3' BROMO 3,4,4',5 TETRAMETHOXY STILBENE; 3' DIHYDROXY 3,4',5 TRIMETHOXY STILBENE; 3' DIMETHYLAMINO 3,4,4',5 TETRAMETHOXY STILBENE; 3' NITRO 3,4,4',5 TETRAMETHOXY STILBENE; 3' O(2'' CHLOROETHYL)COMBRETASTATIN A4; 3' O(2'' HYDROXYETHYL)COMBRETASTATIN A4; 3' O(3'' HYDROXYPROPYL) 3,4,4',5 TETRAMETHOXY STILBENE; 3' O(3'' HYDROXYPROPYL)COMBRETASTATIN A4; 3' O[2'' (1H IMIDAZOL 1 YL)ETHYL]COMBRETASTATIN A4; 3' O[2'' (METHANESULFONYL)ETHYL]COMBRETASTATIN A4; 3' O[2'' (N METHYLPIPERAZINYL)ETHYL]COMBRETASTATIN A4; 3' O[2'' (N MORPHOLINO)ETHYL]COMBRETASTATIN A4; 3' O[2'' (N PIPERIDINYL)ETHYL]COMBRETASTATIN A4; 3' O[2'' (N PYRROLIDINYL)ETHYL]COMBRETASTATIN A4; 3' O[2'' (N PYRROLLYL)ETHYL]COMBRETASTATIN A4; 3' O[2'' (N,N DIETHYLAMINO)ETHYL]COMBRETASTATIN A4; 3' O[2'' (N,N DIMETHYLAMINO)ETHYL]COMBRETASTATIN A4; 3' O[2'' (TRIMETHYLAMINO)ETHYL]COMBRETASTATIN A4 IODIDE; 3' O[BIS(2 CHLOROETHYL)CARBAMOYL]COMBRETASTATIN A4; 3',4 DIHYDROXY 3,4',5 TRIMETHOXY STILBENE; ANTINEOPLASTIC AGENT; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; PRODRUG; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LUNG CARCINOMA; LYMPHATIC LEUKEMIA; MICROTUBULE ASSEMBLY; MOUSE; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PHARYNX CANCER; PROSTATE CANCER; SQUAMOUS CELL CARCINOMA; THYROID CANCER; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BIOPOLYMERS; CELL LINE, TUMOR; COLONY COUNT, MICROBIAL; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; STEREOISOMERISM; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 20444403700     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0205797     Document Type: Article

References (101)

1. For contribution no. 444, refer to: Pettit, G. R.; Lippert, J. W., III; Herald, D. L. A Pinacol Rearrangement/Oxidation Synthetic Route to Hydroxyphenstatin. J. Org. Chem. 2000, 65, 7438-7444.
2. (a) Pinney, K. G.; Bounds, A. D.; Dingeman, K. M.; Mocharla, V. P.; Pettit, G. R.; Bai, R.; Hamel, E. A New Anti-tubulin Agent Containing the Benzo(b)thiophene Ring System. Bioorg. Med. Chem. Lett. 1999, 9, 1081-1086.
3. (b) Miller, T. A.; Bulman, A. L.; Thompson, C. D.; Macdonald, T. L. The Synthesis and Evaluation of Temperature Sensitive Tubulin Toxins. Bioorg. Med. Chem. Lett. 1999, 9, 407-412.
4. (c) Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a Target for Anticancer Drugs: Agents Which Interact with the Mitotic Spindle. Med. Res. Rev. 1998, 18, 259-296.
5. (d) Chaudhuri, A. R.; Seetharamalu, P.; Schwarz, P. M.; Hausheer, F. H.; Ludueña, R. F. The Interaction of the B-ring of Colchicine with α-Tubulin: A Novel Footprinting Approach. J. Mol. Biol. 2000, 303, 679-692.
6. (e) ter Haar, E.; Rosenkranz, H. S.; Hamel, E.; Day, B. W. Computational and Molecular Modeling Evaluation of the Structural Basis for Tubulin Polymerization Inhibition by Colchicine Site Agents. Bioorg. Med. Chem. 1996, 4, 1659-1671.
7. (a) DeVincenzo, R.; Scambia, G.; Ferlini, C.; Distefano, M.; Filippini, P.; Riva, A.; Bombardelli, E.; Pocar, D.; Gelmi, M. L.; Benedetti-Panici, P.; Mancuso, S. Antiproliferative Activity of Colchicine Analogues on MDR-Positive and MDR-Negative Human Cancer Cell Lines. Anti-Cancer Drug Des. 1998, 13, 19-33.
8. (b) Shi, Q.; Verdier-Pinard, P.; Brossi, A.; Hamel, E.; McPhail, A. T.; Lee, K.-H. Antitumor Agents. 172. Synthesis and Biological Evaluation of Novel Deacetamidothiocolchicine-7-ols and Ester Analogs as Antitubulin Agents. J. Med. Chem. 1997, 40, 961-966.
9. (c) Ducray, P.; Lebeau, L.; Mioskowski, C. Synthesis of Lipid Derivatives of Colchicine. Helv. Chim. Acta 1996, 79, 2346-2352.
10. (d) Boye, O.; Brossi, A. Tropolonic Colchicum Alkaloids and Allo Congeners. In The Alkaloids; Brossi, A., Ed.; Academic Press: New York, 1992; Vol. 41, pp 125-176.
11. (e) Muzaffar, A.; Brossi, A.; Lin, C. M.; Hamel, E. Antitubulin Effects of Derivatives of 3′-Dimethylthiocolchine, Methylthio Ethers of Natural Colchicinoids, and Thioketones Derived from Thiocolchicine. Comparison with Colchicinoids. J. Med. Chem. 1990, 33, 567-571.
12. (a) Pettit, G. R.; Toki, B. E.; Herald, D. L.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Chapuis, J. C. Antineoplastic Agents 410. Asymmetric Hydroxylation of trans-Combretastatin A-4. J. Med. Chem. 1999, 42, 1459-1465.
13. (b) Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Chaplin, D. J.; Stratford, M. R. L.; Hamel, E.; Pettit, R. K.; Chapuis, J.-C.; Oliva, D. Antineoplastic Agents 393. Synthesis of the trans-isomer of Combretastatin A-4 Prodrug. Anti-Cancer Drug Des. 1998, 13, 981-993.
14. (c) Pettit, G. R.; Rhodes, M. R. Antineoplastic Agents 389. New Syntheses of the Combretastatin A-4 Prodrug. Anti-Cancer Drug Des. 1998, 13, 183-191.
15. (d) Pettit, G. R.; Singh, S. B.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Schmidt, J. M.; Hogan, F. Antineoplastic Agents. 291. Isolation and Synthesis of Combretastatins A-4, A-5 and A-6. J. Med. Chem. 1995, 38, 1666-1672.
16. (e) Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Isolation and Structure of the Strong Cell Growth and Tubulin Inhibitor Combretastatin A-4. Experientia 1989, 45, 209-211.
17. (f) Lin, C. M.; Singh, S. B.; Chu, P. S.; Dempcy, R. O.; Schmidt, J. M.; Pettit, G. R.; Hamel, E. Interactions of Tubulin with Potent Natural and Synthetic Analogs of the Antimitotic Agent Combretastatin: A Structure-Activity Study. Mol. Pharmacol. 1988, 34, 200-208.
18. (g) Pettit, G. R.; Singh, S. B.; Schmidt, J. M.; Niven, M. L.; Hamel, E.; Lin, C. M. Isolation, Structure, Synthesis and Antimitotic Properties of Combretastatins B-3 and B-4 from Combretum caffrum. J. Nat. Prod. 1988, 51, 517-527.
19. (h) Pettit, G. R.; Singh, S. B.; Niven, M. L.; Hamel, E.; Schmidt, J. M. Isolation, Structure and Synthesis of Combretastatins A-1 and B-1, Potent New Inhibitors of Microtubule Assembly, Derived from Combretum caffrum. J. Nat. Prod. 1987, 50, 119-131.
20. (i) Pettit, G. R.; Cragg, G. M.; Singh, S. B. Antineoplastic Agents 122. Constituents of Combretum caffrum. J. Nat. Prod. 1987, 50, 386-391.
21. (j) Pettit, G. R.; Singh, S. B. Isolation, Structure, and Synthesis of Combretastatin A-2, A-3, and B-2. Can. J. Chem. 1987, 65, 2390-2396.
22. (k) Pettit, G. R.; Singh, S. B.; Cragg, G. M. Synthesis of Natural (-)-Combretastatin. J. Org. Chem. 1985, 50, 3404-3406.
23. (l) Pettit, G. R.; Cragg, G. M.; Herald, D. L.; Schmidt, J. M.; Lohavanijaya, P. Isolation and Structure of Combretastatin. Can. J. Chem. 1982, 60, 1374-1376.
24. (m) Nabha, S. M.; Mohammad, R. M.; Wall, N. R.; Dutcher, J. A.; Salkini, B. M.; Pettit, G. R.; Al-Katib, A. M. Evaluation of Combretastatin A-4 Prodrug in a Non-Hodgkin's Lymphoma Xenograft Model: Preclinical Efficacy. Anti-Cancer Drugs 2001, 12, 57-63.
25. (n) Nabha, S. M.; Wall, N. R.; Mohammad, R. M.; Pettit, G. R.; Al-Katib, A. M. Effects of Combretastatin A-4 Prodrug against a Panel of Malignant Human β-Lymphoid Cell Lines. Anti-Cancer Drugs 2000, 11, 385-392.
26. (a) Mannila, E.; Talvitie, A.; Kolehmainen, E. Antileukemic Compounds Derived from Stilbenes in Picea abies Bark. Phytochemistry 1993, 33, 813-816.
27. (b) Schmitt, E.; Lehmann, L.; Metzler, M.; Stopper, H. Hormonal and Genotoxic Activity of Resveratrol. Toxicol. Lett. 2002, 136, 133-142.
28. (c) Matsuoka, A.; Takeshita, K.; Furuta, A.; Ozaki, M.; Fukuhara, K.; Miyata, N. The 4′-Hydroxy Group is Responsible for the in vitro Cytogenetic Activity of Resveratrol. Mutat. Res. 2002, 521, 29-35.
29. (d) Arichi, H.; Kimura, Y.; Okuda, H.; Baba, H.; Kozawa, K.; Arichi, S. Effects of Stilbene Components of the Roots of Polygonum cuspidatum SIEB ET ZUCC on Lipid-metabolism. Chem. Pharm. Bull. 1982, 30, 1766-1770.
30. (e) Ingham, J. L. 3,5,4′-Trihydroxystilbene as a Phytoalexin from Groundnuts (Arachis hypogeae). Phytochemistry 1976, 15, 1791-1793.
31. (f) Pettit, G. R.; Grealish, M. P.; Jung, M. K.; Hamel, E.; Pettit, R. K.; Chapuis, J.-C.; Schmidt, J. M. Antineoplastic Agents 465. Structural Modification of Resveratrol: Sodium Resverastatin Phosphate. J. Med. Chem. 2002, 45, 2534-2542.
32. (a) Gordaliza, M.; Castro, M. A.; del Corral, J. M. M.; Lopez-Vazquez, M. L.; Garcia, P. A.; San Feliciano, A.; Garavia-Gravalos, M. D.; Broughton, H. Preparation and Cytotoxicity of Podophyllotoxin Derivatives Lacking the Lactone Ring. Tetrahedron 1997, 53, 15742-15760.
33. (b) Utsugi, T.; Shibata, J.; Sugimoto, Y.; Aoyagi, K.; Wierzba, K.; Kobunai, T.; Terada, T.; Oh-hara, T.; Tsuruo, T.; Yamada, Y. Antitumor Activity of a Novel Podophyllotoxin Derivative (TOP-53) against Lung Cancer and Lung Metastatic Cancer. Cancer Res. 1996, 56, 2809-2814.
34. (c) Kamal, A.; Atchison, K.; Daneshtalab, M.; Micetich, R. G. Synthesis of Podophyllotoxin Congeners as Potential DNA Topoisomerase II Inhibitors. Anti-Cancer Drug Des. 1995, 10, 545-554.
35. (d) Lee, K.-H.; Imakura, Y.; Haruna, M.; Beeers, S. A.; Thurston, L. S.; Dai, H.-J.; Chen, C.-H.; Liu, S.-Y.; Cheng, Y.-C.; Antitumor Agents. 107. New Cytotoxic 4-Alkylamino Analogs of 4′-Demethyl-Epipodophyllotoxin as Inhibitors of Human DNA Topoisomerase II. J. Nat. Prod. 1989, 52, 606-613.
36. (a) Wickdramaratne, D. B. M.; Pengsuparp, T.; Mar, W.; Chai, H.-B.; Chagwedera, T. E.; Beecher, C. W. W.; Farnsworth, N. R.; Kinghorn, A. D.; Pezzuto, J. M.; Cordell, G. A. Novel Antimitotic Dibenzocyclo-octadiene Lignan Constituents of the Stem Bark of Steganotaenia araliacea. J. Nat. Prod. 1993, 56, 2083-2090.
37. (b) Tomioka, K.; Ishiguro, T.; Mizuguchi, H.; Komeshima, N.; Koga, K; Tsukagoshi, S.; Tsuruo, T.; Tashiro, T.; Tanida, S.; Kishi, T. Absolute Structure-Cytotoxic Activity Relationships of Steganacin Congeners and Analogues. J. Med. Chem. 1991, 34, 54-57.
38. (c) Schiff, P. B.; Kende, A. S.; Horwitz, S. B. An Inhibitor of Hela Cell Growth and Microtubule Assembly in vitro. Biochem. Biophys. Res. Commun. 1978, 85, 737-746.
39. (d) Wang, R. W.-J.; Rebhun, L. I.; Kupchan, S. M. Antimitotic and Antitubulin Activity of the Tumor Inhibitor Steganacin. Cancer Res. 1977, 37, 3071-3079.
40. (a) McGown, A. T.; Fox, B. W. Differential Cytotoxicity of Combretastatins A-1 and A-4 in Two Daunorubicin-Resistant P388 Cell Lines. Cancer Chemother. Pharmacol. 1990, 26, 79-81.
41. (b) Jiang, J. B.; Hesson, D. P.; Dusak, B. A.; Dexter, D. L.; Kang, G. L.; Hamel, E. Synthesis/Biological Evaluation of 2-Styrylquinazolin-4(3H)-ones, a New Class of Antimitotic Anticancer Agents Which Inhibit Tubulin Polymerization. J. Med. Chem. 1990, 33, 1721-1728.
42. (c) Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic Natural Products Combretastatin A-4 and Combretastatin A-2: Studies on the Mechanism of Their Inhibition of the Binding of Colchicine to Tubulin. Biochemistry 1989, 28, 6984-6991.
43. (d) McGown, A. T.; Fox, B. W. Structural and Biochemical comparison of the Antimitotic Agents Colchicine, Combretastatin A-4 and Amphethinile. Anti-Cancer Drug Des. 1989, 3, 249-254.
44. (a) Chaplin, D. J.; Pettit, G. R.; Hill, S. A. Anti-Vascular Approaches to Solid Tumour Therapy: Evaluation of Combretastatin A4 Phosphate. Anticancer Res. 1999, 19, 189-196.
45. (b) Dark, G. G.; Hill, S. A.; Prise, V. E.; Tozer, G. M.; Pettit, G. R.; Chaplin, D. J. Combretastatin A-4, an Agent That Displays Potent and Selective Toxicity toward Tumor Vasculature. Cancer Res. 1997, 57, 1829-1834.
46. (a) Aleksandrzak, K.; McGown, A. T.; Hadfield, J. A. Antimitotic Activity of Diaryl Compounds with Structural Features Resembling Combretastatin A-4. Anti-Cancer Drugs 1998, 9, 545-550.
47. (b) Hatanaka, T.; Fujita, K.; Obsumi, K.; Nakagawa, R.; Fukuda, Y.; Nihei, Y.; Suga, Y.; Akiyama, Y.; Tsuji, T. Novel B-Ring Modified Combretastatin Analogues: Syntheses and Antineoplastic Activity. Bioorg. Med. Chem. Lett. 1998, 8, 3371-3374.
48. (c) Ohsumi, J.; Hatanaka, T.; Fujita, K.; Nakagawa, R.; Fukuda, Y.; Hihei, Y.; Suga, Y.; Morinaga, Y.; Akiyama, Y.; Tsuji, T. Syntheses and Antitumor Activity of cis-Restricted Combretastatins: 5-membered Heterocyclic Analogues. Bioorg. Med. Chem. Lett. 1998, 8, 3153-3158.
49. (d) Medarde, M.; Ramos, A.; Caballero, E.; Peláez-Lamamié de Clairac, R.; López, L.; Grávalos, D. G.; Feliciano, A. S. Synthesis and Antineoplastic Activity of Combretastatin Analogues: Heterocombretastatins. Eur. J. Med. Chem. 1998, 33, 71-77.
50. (e) Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. Novel Combretastatin Analogues Effective against Murine Solid Tumors: Design and Structure-Activity Relationships. J. Med. Chem. 1998, 41, 3022-3032.
51. (f) Woods, J. A.; Hadfield, J. A.; Pettit, G. R.; Fox, B. W.; McGown, A. T. The Interaction with Tubulin of a Series of Stilbenes Based on Combretastatin A-4. Br. J. Cancer 1995, 71, 705-711.
52. (g) Gwaltney, S. L., II; Imade, H. M.; Barr, K. J.; Li, Q.; Gehrke, L.; Credo, R. B.; Warner, R. B.; Lee, J. Y.; Kovar, P.; Wang, J.; Nukkala, M. A.; Zielinski, N. A.; Frost, D.; Ng, S.-C.; Sham, H. L. Novel Sulfonate Analogues of Combretastatin A-4: Potent Antimitotic Agents. Bioorg. Med. Chem. Lett. 2001, 11, 871-874.
53. (h) Lawrence, N. J.; Rennison, D.; Woo, M.; McGown, A. T.; Hadfield, J. A. Antimitotic and Cell Growth Inhibitory Properties of Combretastatin A-4 Like Ethers. Bioorg. Med. Chem. Lett. 2001, 11, 51-54.
54. (i) Ohsumi, K.; Hatanaka, T.; Nakagawa, R.; Fukuda, Y.; Morinaga, Y.; Suga, Y.; Nihei, Y.; Ohishi, K.; Akiyama, Y.; Tsuji, T. Synthesis and Antitumor Activities of Amino Acid Prodrugs of Amino-Combretastatins. Anti-Cancer Drug Des. 1999, 14, 539-548.
55. (j) Cushman, M.; Nagarathnam, D.; Gopal, D.; He, H.-M.; Lin, C. M.; Hamel, E. Synthesis and Evaluation of Analogues of (Z)-1-(4-Methoxyphenyl)-2-(3, 4,5-trimethoxyphenyl)ethene as Potential Cytotoxic and Antimitotic Agents. J. Med. Chem. 1992, 35, 2293-2306.
56. Vedejs, E.; Peterson, M. J. In Topics in Stereochemistry; Eliel, E. L., Wilen, S. H., Eds.; John Wiley & Sons: New York, 1994; Vol. 21, pp 1-125.
57. Asakawa, Y.; Tanikawa, K.; Aratani, T. New Substituted Bibenzyls of Frullania brittoniae subsp. truncatifolia. Phytochemistry 1976, 15, 1057-1059.
58. (a) Fieser, L. F. 1,2-Aminonaphthol Hydrochloride (2-Naphthol, 1-Amino-, Hydrochloride). Org. Synth. 1943, 35-39.
59. (b) Fieser, L. F. 1,4-Aminonaphthol Hydrochloride (1-Naphthol, 4-Amino-, Hydrochloride). Org. Synth. 1943, Collect. Vol. 2, 39-42.
60. Ramadas, K.; Srinivasan, N. Iron-Ammonium Chloride-a Convenient and Inexpensive Reductant. Synth. Commun. 1992, 22, 3189-3195.
61. Yoo, S.; Lee, S.-L. Reduction of Organic Compounds with Sodium Borohydride-Copper (II) Sulfate System. Synth. Lett. 1990, 419-420.
62. Han, B. H.; Jang, D. G. Montmorillonite Catalyzed Reduction of Nitroarenes with Hydrazine. Tetrahedron Lett. 1990, 31, 1181-1182.
63. Li, H.; Zhang, R.; Wang, H.; Pan, Y.; Shi, Y. A Convenient and Mild Synthetic Route to Aminoarenes by Reduction of Nitroarenes with Activated Nickel and Hydrazine Hydrate. Synth. Commun. 1997, 27, 3047-3052.
64. Nose, A.; Kudo, T. Reduction with Sodium Borohydride-Transition Metal Salt Systems. I. Reduction of Aromatic Nitro Compounds with the Sodium Borohydride-Nickelous Chloride System. Chem. Pharm. Bull. 1981, 29, 1159-1161.
65. (a) Pinney, K. L., personal communication,
66. (b) Ohsumi, K.; Tsuji, T.; Morinaga, Y.; Ohishi, K. Stilbene Derivatives and Pharmaceutical Compositions Containing Them. U.S. Patent No. 5,525,-632, 1996; 7 pp.
67. (c) Hatanaka, T.; Ohsumi, K.; Tsuji, T.; Nihei, Y.; Nakagawa, R.; Ohishi, K. Stilbene Compounds and Pharmaceutical Compositions Containing Them. U.S. Patent No. 5,-674,906, 1997; 13 pp.
68. Bachelor, F. W.; Loman, A. A.; Snowdon, L. R. Synthesis of Pinosylvin and Related Hardwood Stilbenes. Can. J. Chem. 1970, 48, 1554-1557.
69. (a) Baker, R.; Sims, R. J. A Convenient Modification of the Wadsworth-Emmons Method of Olefin Formation Using a Crown Ether. Synthesis 1981, 117.
70. (b) Baker, R.; Sims, R. J. Synthesis of Pallescensin-E: Use of a Crown Ether in the Wadsworth Procedure for Olefin Formation. Tetrahedron Lett. 1981, 22, 161-162.
71. Magarian, R. A.; Avor, K. S.; Overacre, L. B.; Kunchandy, J.; Paxton, T. R. Synthesis and Biological Evaluation of Basic Side Chain Derivatives of Analog II as Pure Antiestrogens and Antitumor Agents. Anti-Cancer Drug Des. 1995, 10, 311-331.
72. Qian, X.; Abul-Hajj, Y. J. Synthesis and Biological Activity of 17β-Substituted Estradiol. J. Steroid Biochem. 1988, 28, 657-664.
73. Günther, H. In NMR Spectroscopy: Basic Principles, Concepts, and Applications in Chemistry, 2nd ed.; Wiley. West Sussex, England, 1995; pp 15-52.
74. (a) Monaco, R. R.; Gardiner, W. C.; Kirschner, S. Semiempirical Studies of Ring Twisting in cis-Stilbene and Related Biomolecules. Int. J. Quantum Chem. 1999, 71, 57-62.
75. (b) Nandy, P.; Banerjee, S.; Gao, H.; Hui, M. B. V.; Lien, E. J. Quantitative Structure-Activity Relationship Analysis of Combretastatins: A Class of Novel Antimitotic Agents. Pharm. Res. 1991, 8, 776-781.
76. (a) Sato, M.; Rippy, M. K.; Bryant, H. U. Raloxifene, Tamoxifen, Nafoxidine, or Estrogen Effects on Reproductive and Nonreproductive Tissues in Ovariectomized Rats. FASEB J. 1996, 10, 905-912.
77. (b) Horwitz, K. B.; McGuire, W. L. Nuclear Mechanism of Estrogen Action. Effect of Estradiol and Antiestrogens on Estrogen Receptors and Nuclear Receptor Processing. J. Biol. Chem. 1978, 253, 8185-8191.
78. (a) Somjen, D.; Waisman, A.; Kaye, A. M. Tissue Selective Action of Tamoxifen Methiodide, Raloxifene and Tamoxifen on Creatine Kinase B Activity in vitro and in vivo. J. Steroid Biochem. Mol. Biol. 1996, 59, 389-396.
79. (b) Jordan, V. C.; Gosden, B. Importance of the Alkylaminoethoxy Side-Chain for the Estrogenic and Antiestrogenic Actions of Tamoxifen and Trioxifene in the Immature Rat Uterus. Mol. Cell. Endocrinol. 1982, 27, 291-299.
80. (c) Stauffer, S. R.; Huang, Y. R.; Aron, Z. D.; Coletta, C. J.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Triarylpyrazoles with Basic Side Chains: Development of Pyrazole-Based Estrogen Receptor Antagonists. Bioorg. Med. Chem. 2001, 9, 151-161.
81. (a) Jarman, M.; Leung, O.-T.; Leclercq, G.; Devleeschouwer, N.; Stoessel, S.; Coombes, R. C.; Skilton, R. A. Analogues of Tamoxifen: The Role of the Basic Sidechain. Application of a Whole-Cell Oestrogen-Receptor Binding Assay to N-Oxides and Quaternary Salts. Anti-Cancer Drug Des. 1986, 1, 259-268.
82. (b) Foster, A. B.; McCague, R.; Seago, A.; Leclercq, G.; Stoessel, S.; Roy, F. Modification of the Basic Side Chain in Tamoxifen: Effects on Microsomal Metabolism and in vitro Biological Activity. Anti-Cancer Drug Des. 1986, 1, 245-257.
83. Hamel, E. Antimitotic Natural Products and Their Interactions with Tubulin. Med. Res. Rev. 1996, 16, 207-231.
84. Pinney, K. G.; Mejia, M. P.; Villalobos, V. M.; Rosenquist, B. E.; Pettit, G. R.; Verdier-Pinard, P.; Hamel, E. Synthesis and Biological Evaluation of Aryl Azide Derivatives of Combretastatin A-4 as Molecular Probes for Tubulin. Bioorg. Med. Chem. Lett. 2000, 8, 2417-2425.
85. Carpio, H.; Galeazzi, E.; Greenhouse, R.; Guzman, A.; Valarde, E.; Antonio, Y.; Franco, F.; Leon, A.; Perez, V.; Salas, R.; Valdes, D.; Ackrell, J.; Cho, D.; Gallegra, P.; Halpern, O.; Koehler, R.; Maddox, M. L.; Muchowski, J. M.; Prince, A.; Tegg, D.; Thurber, T. C.; Van Horn, A. R.; Wren, D. Synthesis of 1,2-Dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic Acids and Homologous Pyridine and Azepine Analogues Thereof. Can. J. Chem. 1982, 60, 2295-2312.
86. (a) Montginoul, C.; Richard, M. J.; Vigne, C.; Giral, L. Synthesis of Aminoalkylbenzyltertiobutylketones. Ann. Pharm. Fr. 1985, 43, 249-255.
87. (b) Bandi, A.; Sala, A.; Angelo Soresinetti, P. Synthesis of New Imidazole Derivatives as Potential Inhibitors of Thromboxane Synthetase. J. Heterocycl. Chem. 1990, 27, 215-219.
88. (a) Gump, W. S.; Nikawitz, E. J. U.S. Patent 2 533 243, 1950; Chem. Abstr. 1950, 45, 4271c.
89. (b) Bagley, J. R.; Thomas, S. A.; Rudo, F. G.; Spencer, H. K.; Doorley, B. M.; Ossipov, M. H.; Jerussi, T. P.; Benvenga, M. J.; Spaulding, T. New 1-(Heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl Methyl Ester and Methylene Methyl Ether Analgesics. J. Med. Chem. 1991, 34, 827-841.
90. Hawes, E. M.; Davis, H. L. Intramolecular Nucleophilic Cyclization of 3-Substituted Pyridylalkylamines onto the 2-Position of the Pyridine Ring. J. Heterocycl. Chem. 1973, 10, 39-42.
91. Gough, G. A. C.; King, H. Trypanocidal Action and Chemical Constitution. Part VIII. Derivatives of β-Aminoethyl and γ-Aminopropyl-arsinic Acids. J. Chem. Soc. 1928, 2426-2447.
92. Johnson, T. B.; Bengls, R. Hydantoins: Synthesis of the Hydantoin of 3-Amino-Tyrosine. J. Am. Chem. Soc. 1912, 34, 1054-1061.
93. Green, G. D.; Weinscherik, J. I., III; Mulvaney, J. E.; Hall, H. K., Jr. Synthesis of Polyesters Containing a Nonrandomly Placed Highly Polar Repeating Unit. Macromolecules 1987, 20, 722-726.
94. Singh, S. B.; Pettit, G. R. Isolation, Structure, and Synthesis of Combretastatin C-1. J. Org. Chem. 1987, 54, 4105-4114.
95. Mann, F. G. Hofmann's Ethylene Bases. Synthesis of β,β′- Diaminodiethylamine and of β,β′-Diaminodiethylmethylamine. J. Chem. Soc. 1934, 461-466.
96. Dave, M. A.; Kulkami, A. B. Synthesis of Dimethylamino Aromatic Ketones and Aldehydes. II. Indian J. Chem. 1975, 13, 33-34.
97. SMART for Windows NT, v. 5.605; Bruker AXS Inc.: Madison, WI, 2000.
98. XPREP-The automatic space group determination program in the SHELXTL (se ref 44).
99. Blessing, R. H. Acta Crystallogr. 1995, A51, 33-38.
100. SHELXTL-NT, Version 5.10; Bruker AXS Inc.: Madison, WI, 1997. An integrated suite of programs for the determination of crystal structures from diffraction data. This package includes, among other, XPREP (an automatic space group determination program), SHELXS (a structure solution program via Patterson or direct methods), and SHELXL (structure refinement software).
101. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests; Approved standard M2-A6; NCCLS: Wayne, PA, 1997.